The Dragon PLC Trial (DRAGON-PLC)

计划入组 358 人 · 首次发布于 2025 年 4 月 6 日

Digital Silence and Mental Health

计划入组 100 人 · 首次发布于 2025 年 8 月 29 日

Sedative-Anxiolytic Effects on Simulated Driving Performance

计划入组 15 人 · 首次发布于 2017 年 9 月 29 日

GalNAc-conjugated siRNA therapeutic, Silence Therapeutics

personalized neoantigen/cancer testis antigen nanovaccine (cancer), Nanjing University

SLN-226

SILENCE THERAPEUTICS, INC.

United States

Silence Therapeutics GmbH

Germany

Celsus Therapeutics Plc

United Kingdom

Silence Therapeutics Reports Positive Phase II Zerlasiran Data and Phase I Divesiran Results, Extends Cash Runway into 2027

Silence Therapeutics Completes Enrollment in Phase 2 Trial of First-in-Class siRNA for Polycythemia Vera

Novel Hypercholesterolemia Drugs Market to Reach USD 42.8 Billion by 2036 as Oral PCSK9 Inhibition and Gene Editing Expand Treatment Options